PURPOSE OF REVIEW Osteoporotic fractures are common and can be devastating. Although multiple different medications with unique mechanisms of action are currently available in our arsenal to attempt to prevent fractures, an ideal opportunity in which to use these medications in combination remains elusive. New data has emerged over the past few years in regards to assessing which medication combinations may be productive and efficacious. RECENT FINDINGS Previous studies performed using different medications to treat osteoporosis in combination proved either not overall beneficial or inconclusive. More recent studies suggest a potential additive and synergistic benefit of certain combination therapies, particularly with the use of denosumab and teriparatide in select situations. SUMMARY The knowledge of modern data as to when the potential use of combination therapy in treating osteoporosis may be useful is critical to the acquisition of proficiency in the ideal management of our patients at highest risk for fracture. Although not recommended yet by current guidelines, the advancement of expertise in this field, both in research studies, and clinical practice, will help us discern how to best consider the use of combination treatment now and in the future.

中文翻译：

---

联合疗法治疗骨质疏松症。

审查目的骨质疏松性骨折很常见，并且可能具有破坏性。尽管目前我们的军械库中有多种具有独特作用机理的药物可以预防骨折，但是结合使用这些药物的理想机会仍然难以捉摸。过去几年中出现了有关评估哪些药物组合可能有效和有效的新数据。最近的发现以前使用不同药物联合治疗骨质疏松症的研究证明，总体上不是有益的，也不是结论性的。最近的研究表明，某些联合疗法可能具有潜在的累加和协同效益，尤其是在某些情况下使用地诺单抗和特立帕肽。发明内容关于何时可能使用联合疗法治疗骨质疏松症可能有用的现代数据的知识对于在骨折风险最高的患者的理想治疗中获得熟练度至关重要。尽管目前的指南尚未推荐，但无论是研究还是临床实践，该领域专业知识的发展都将帮助我们辨别如何最好地考虑现在和将来使用联合治疗。